Platinum complexes with mononitrile-containing ligands

Abstract

Disclosed herein are novel platinum-based complexes possessing one nitrile substituent group (mononitrile) covalently-bonded to the platinum, one or more nitrogen donor ligands capable of forming hydrogen bonds with the bases in DNA or RNA and leaving groups (i.e., L1 and L2 )which can be hydrolyzed in vivo to active species, which can then form coordinate adducts with DNA or RNA at the Guanine or Adenine bases thereof. Also disclosed herein are the reaction schemes for the synthesis of said platinum complexes, as well as methods of treatment of various types of cancer by the administration of a pharmaceutically-effective dose of said novel platinum complexes.

Description

[0001] This application claims priority to Provisional Application Serial No. 60 / 695,638, filed June 30, 2005 and entitled "Platinum Complexes with Mononitrile-Containing Ligands." Background of the invention [0002] The present invention relates to novel platinum complexes with mononitrile-containing ligands, pharmaceutically acceptable salts and / or derivatives thereof and for the synthesis of these platinum complexes with mononitrile-containing ligands, and their pharmaceutical Methods of Acceptable Salts and / or Derivatives. More specifically, the present invention relates to the use of novel platinum complexes, pharmaceutically acceptable salts and / or derivatives thereof, with ligands containing mononitriles, for the purpose of inhibiting the growth of cancer cells, having Pharmaceutically acceptable formulations of platinum complexes of ligands containing nitriles and derivatives thereof and methods of administration of platinum complexes of ligands containing mononitrile...

AI Technical Summary

Problems solved by technology

Therefore, their adducts with DNA bases may be more sensitive to tumor-mediated platinum-DNA repair mechanisms

Images